AC Immune (NASDAQ:ACIU) Downgraded by StockNews.com

AC Immune (NASDAQ:ACIU) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

Separately, HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of AC Immune in a research report on Wednesday, September 18th.

AC Immune Trading Up 0.8 %

Shares of NASDAQ ACIU opened at $3.78 on Tuesday. AC Immune has a one year low of $2.20 and a one year high of $5.14. The firm has a market capitalization of $373.84 million, a PE ratio of -5.48 and a beta of 1.24. The business has a 50-day moving average price of $3.44 and a two-hundred day moving average price of $3.38.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.67). The business had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $91.60 million. Research analysts anticipate that AC Immune will post -0.89 EPS for the current year.

Institutional Investors Weigh In On AC Immune

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC purchased a new stake in shares of AC Immune during the 2nd quarter worth about $218,000. Renaissance Technologies LLC raised its stake in shares of AC Immune by 26.4% during the 2nd quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock worth $2,602,000 after purchasing an additional 136,300 shares in the last quarter. Vanguard Capital Wealth Advisors purchased a new stake in shares of AC Immune during the 2nd quarter worth about $56,000. Assenagon Asset Management S.A. raised its stake in shares of AC Immune by 294.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock worth $1,755,000 after purchasing an additional 328,312 shares in the last quarter. Finally, Silverberg Bernstein Capital Management LLC purchased a new stake in shares of AC Immune during the 2nd quarter worth about $40,000. 51.36% of the stock is owned by hedge funds and other institutional investors.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.